Regend Therapeutics (China)

Regend Therapeutics Limited (also presented as Regend Corp) is a Chinese biotechnology company focused on regenerative medicine. Founded in 2015 and headquartered in Xinghua, China, the company discovers, develops and commercializes cell therapeutic products intended to regenerate human organs. Its stated mission is to deliver therapies to patients with severe, irreversible organ damage that conventional drugs cannot address, using tissue-specific epithelial stem cells — also called progenitor cells — to repair injured organ structure and restore organ function. The company positions itself at the frontier of regenerative medicine, arguing that unlike traditional pharmaceuticals or medical devices that mainly relieve symptoms or provide partial repair, regenerative medicine seeks to restore the structural and functional integrity of damaged tissues or organs. Its lead programs target major chronic diseases with significant unmet need, notably Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD). Regend's most advanced asset is REGEND001, also called Aeriotemcel, an innovative autologous lung progenitor cell therapy for chronic and progressive pulmonary diseases. According to the company, Phase II clinical study results for REGEND001 demonstrate potential to significantly and sustainably improve lung gas transfer capacity in COPD and IPF patients by repairing and regenerating damaged alveolar structures. The company states that in 2025 it completed Phase II clinical trials in COPD and IPF indications respectively, and describes itself as transitioning from a clinical stage to early commercialization. The company is led by Professor Wei Zuo, described as a distinguished scientist and the leader of a project under the National Key R&D Plan of China for Stem Cell Translational Research. Regend was established by a team of internationally trained scientific leaders with expertise in regenerative biology and translational medicine, and it leads a National Key R&D Plan of China project in "Stem Cell Research and Organ Regeneration." Its mission slogan is "Recreate Life, Restore Health." Regend has built multiple proprietary technology platforms, including the R-Clone Epithelial Stem Cell Cloning Platform, the IntelCell Intelligent Cell Platform, MIX0109 Tissue & Cell Rejuvenation Technology, the Chimera Chimeric Animal Model Platform, the REGEN-Wukong AI Platform, and specialized organ-specific validation platforms. Leveraging these platforms, the company has assembled a pipeline of globally innovative regenerative medicine products. It remains a private company and operates primarily in the Chinese market.

Regend Therapeutics Limited was founded in 2015 as a biotechnology company dedicated to discovering, developing and commercializing innovative cell therapeutic products to regenerate human organs. It was established by a team of internationally trained scientific leaders with deep expertise in regenerative biology and translational medicine, and is led by Professor Wei Zuo, described as a distinguished scientist and the leader of a project under the National Key R&D Plan of China for Stem Cell Translational Research. The company is headquartered in Xinghua, China. From its founding, Regend pursued a regenerative-medicine framework based on tissue-specific epithelial stem cells, also called progenitor cells, to repair injured organ structure and restore organ function. The company argues that this approach differs fundamentally from traditional pharmaceuticals or medical devices that mainly alleviate symptoms or provide partial repair, aiming instead at systemic regeneration in degenerative and damaged diseases. Over time Regend built a set of proprietary technology platforms: the R-Clone Epithelial Stem Cell Cloning Platform, the IntelCell Intelligent Cell Platform, MIX0109 Tissue & Cell Rejuvenation Technology, the Chimera Chimeric Animal Model Platform, the REGEN-Wukong AI Platform, and specialized organ-specific validation platforms. It also leads a National Key R&D Plan of China project in "Stem Cell Research and Organ Regeneration." Leveraging these platforms, the company assembled a pipeline of globally innovative regenerative medicine products. Its lead program, REGEND001 (also called Aeriotemcel), is an innovative autologous lung progenitor cell therapy for a range of chronic and progressive pulmonary diseases. The company reports that Phase I and Phase II clinical data have demonstrated its potential to reverse damage and to significantly and sustainably improve lung gas transfer capacity in COPD and IPF patients by repairing and regenerating damaged alveolar structures. In 2025, Regend completed Phase II clinical trials in COPD and IPF indications respectively. By the mid-2020s the company described itself as transitioning from a clinical stage to early commercialization, with a focus on serious chronic diseases where conventional treatments remain largely symptomatic and unable to reverse underlying pathology. Its stated ultimate aim is to extend longevity and improve quality of life, under the mission "Recreate Life, Restore Health."

• 2025

  Completed Phase II clinical trials of REGEND001 in COPD and IPF indications.

• 2015

  Regend Therapeutics founded as a regenerative-medicine biotechnology company.

Frontier regenerative-medicine biotech developing tissue-specific epithelial stem/progenitor cell therapies for severe chronic organ diseases with high unmet need.

• REGEND001 (Aeriotemcel)

  Innovative autologous lung progenitor cell therapy for chronic and progressive pulmonary diseases; Phase II results reported potential to improve lung gas transfer capacity in COPD and IPF patients by repairing and regenerating damaged alveolar structures.

1. 1Regend Corp official websiteregend.cn
2. 2About us - Regend Corpregend.cn
3. 3About us - Regend Corpregend.cn
4. 4Regend Therapeutics (China) - Wikidatawikidata.org